S&T | Researchers culture novel coronavirus, may help in drug testing & vaccine development

0
144
Researchers culture novel coronavirus, may help in drug testing
Researchers culture novel coronavirus, may help in drug testing

PIB News Update: The Centre for Cellular and Molecular Biology (CCMB) has established stable cultures of coronavirus (SARS-CoV-2) from patients’ samples. Virologists at CCMB have isolated infectious viruses from several isolates. The ability to culture the virus in lab enables CCMB to work towards vaccine development and testing of potential drugs to fight COVID-19.

Novel coronavirus enters human cell by binding with the ACE-2 receptor on the cell surface. Not all cells have ACE-2 receptors. Human epithelial cells in the respiratory tract copiously express ACE-2 receptors, causing respiratory disease in the infected patient. However, we cannot grow human epithelial cells in lab. “Currently, primary epithelial cells generated from human origins do not grow for many generations in labs, which is key to culturing viruses continuously. At the same time, the labs that are growing the virus need an ‘immortal’ cell line”, says Dr Krishnan H Harshan, Principal Scientist, CCMB. They use Vero cells (kidney epithelial cell lines from green African monkey), which express ACE-2 proteins and carry a cell division that allows them to proliferate indefinitely.

But why cultivate a dreadful germ? If we culture a large amount of the virus and inactivate them, then it can be used as inactivated virus vaccine. Once we inject the inactivated virus, the human immune system triggers the production of germ-specific antibodies. One can inactivate the virus by heat or chemical means. The inactivated virus can trigger antibody response, but does not infect and make us sick as they cannot reproduce.

For the development of antibodies or antidots, virus cultures are important. Inactivated viruses can trigger antibody response in other mammalian hosts in addition to humans. Various such hosts are currently under test for their efficiency of antibody response. Such antibodies generated in these non-human hosts can be purified, processed and collected. The antibodies can be used as therapeutic intervention for patients suffering from the infection.  Such antibodies can trigger antiviral response upon injection into humans and have the potential of limiting the infection. Administering antibodies does not provide immunity like a vaccine does, but can be considered as anti-dotes against the virus.

These cultures may also be helpful in the process of drug screening. Potential drugs can be tested against the virus in a test-tube for their efficacy.

“Using the Vero cell lines to grow the coronavirus, CCMB is now in a position to isolate and maintain viral strains from different regions. We are working towards producing viruses in huge quantities that can be inactivated, and used in vaccine development and antibody production for therapeutic purposes”, says CCMB Director, Dr Rakesh Mishra. CCMB has also started testing potential drugs with other partners such as the Defence Research Development Organisation (DRDO) using this viral culture.

“We hope that such systems are replicated at multiple research institutes and private companies to become a useful resource in the fight against this pandemic as well as for future preparedness”, said Dr Mishra.

 

Previous articleProvisional Estimates of Annual National Income, 2019-20 and Qtly Estimates (q4) of GDP, 2019-20
Next articleNew drug combination being tested to conquer COVID-19 by Albert Einstein College of Medicine
Saurabh
Saurabh Sinha, Editor of IndianBureaucracy.com, is known for his credible, precise and insightful coverage of governance, civil services and administrative developments in India. Under his leadership, the portal has grown into a trusted national platform for accurate updates, appointments and policy movements within the bureaucratic ecosystem. Saurabh’s strong professional networking and deep understanding of government functioning enable him to present timely, reliable and well-contextualised information to readers across sectors. As a thought-driven editor, he promotes informed dialogue on governance reforms while maintaining high editorial standards. His calm, consistent and detail-oriented approach continues to strengthen the portal’s reputation. इंडियनब्यूरोक्रेसी.कॉम के संपादक सौरभ सिन्हा देश की नौकरशाही, शासन व्यवस्था और प्रशासनिक गतिविधियों की विश्वसनीय तथा संतुलित रिपोर्टिंग के लिए जाने जाते हैं। उनके नेतृत्व में यह पोर्टल नियुक्तियों, नीतिगत बदलावों और प्रशासनिक खबरों का एक भरोसेमंद राष्ट्रीय स्रोत बन चुका है। शासन तंत्र की गहरी समझ और मजबूत पेशेवर नेटवर्क के कारण सौरभ पाठकों को समयबद्ध, सटीक और संदर्भित जानकारी प्रदान करते हैं। एक विचारशील संपादक के रूप में वे सुशासन, पारदर्शिता और सुधारों पर सकारात्मक संवाद को बढ़ावा देते हैं। उनकी शांत, सूक्ष्म और पेशेवर संपादकीय शैली पोर्टल की प्रतिष्ठा को लगातार मजबूत कर रही है।